UT Health San Antonio

Oral pill improves care of patients with bone marrow cancer: Study

<p>Momelotinib, an oral pill taken once a day, significantly improved outcomes of patients treated for myelofibrosis (MF), a rare but fatal bone marrow cancer, researchers reported June 7.&nbsp;Ruben Mesa, MD, FACP, executive director of the&nbsp;Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, presented results of the MOMENTUM phase 3 randomized [&hellip;]</p>

Share This Story